New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
10:05 EDTFMS, BAXBaxter denied Supreme Court appeal of Fresenius Medical ruling
The Supreme Court declined to hear an appeal filed by Baxter (BAX) over a patent dispute with Fresenius Medical (FMS). The high court decision means the Court of Appeals for the Federal Circuit's decision to overturn a lower court judgment of almost $24M in favor of Baxter remains intact. Reference Link
News For BAX;FMS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 27, 2014
07:23 EDTBAXAmerican College of Surgeons holds a conference
Subscribe for More Information
07:22 EDTBAXAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
October 24, 2014
09:02 EDTBAXBaxter says FDA approves Obizur for acquired hemophilia A
Subscribe for More Information
October 22, 2014
13:35 EDTFMSFresenius Medical acquires National Cardiovascular Partners
Fresenius Medical Care announced the acquisition of National Cardiovascular Partners, or NCP. The parties involved agreed not to disclose the financial terms of the acquisition. The company expects NCP to generate in excess of $200M in revenue in 2015 and expects the investment to be accretive to earnings in the first year after closing. The investment will be financed through available cash and committed credit facilities, supplemented by additional debt financing. NCP is the leading operator of endovascular, vascular and cardiovascular services in the comfort and convenience of the outpatient setting. In partnership with over 200 physicians, NCP operates 21 outpatient vascular centers in six states.
October 21, 2014
06:29 EDTBAXBaxter management to meet with Leerink
Subscribe for More Information
October 20, 2014
09:04 EDTBAXBaxter, Halozyme launch HYQVIA in U.S.
Subscribe for More Information
October 19, 2014
14:18 EDTFMSFresenius, others explore bid for Danone medical nutrition unit, Reuters says
Subscribe for More Information
October 16, 2014
09:04 EDTBAXBaxter says spin-off of BioScience division on track for mid-2015 completion
Subscribe for More Information
09:02 EDTBAXBaxter says it still has not experienced competition for cyclophosphamide
Subscribe for More Information
08:38 EDTBAXBaxter expects divestiture of vaccines business to Pfizer to close in Q4
Subscribe for More Information
07:03 EDTBAXBaxter sees FY14 continuing ops EPS $4.86-$4.89, consensus $5.16
Subscribe for More Information
07:02 EDTBAXBaxter sees Q4 continuing ops EPS $1.30-$1.33, consensus $1.41
Sees Q4 sales growth approx. 3% excluding the impact of foreign currency. Including the impact of foreign currency, the company expects reported sales to be flat to 2013 levels. Consensus is $4.39B.
07:01 EDTBAXBaxter reports Q3 adjusted EPS $1.35, consensus $1.31
Reports Q3 revenue $4.2B, consensus $4.2B.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use